GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Cash And Cash Equivalents

Grand Pharmaceutical Group (HKSE:00512) Cash And Cash Equivalents : HK$1,340 Mil (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Cash And Cash Equivalents?

Grand Pharmaceutical Group's quarterly cash and cash equivalents declined from Dec. 2022 (HK$1,444.01 Mil) to Jun. 2023 (HK$693.61 Mil) but then increased from Jun. 2023 (HK$693.61 Mil) to Dec. 2023 (HK$1,339.71 Mil).

Grand Pharmaceutical Group's annual cash and cash equivalents declined from Dec. 2021 (HK$1,752.86 Mil) to Dec. 2022 (HK$1,444.01 Mil) and declined from Dec. 2022 (HK$1,444.01 Mil) to Dec. 2023 (HK$1,339.71 Mil).


Grand Pharmaceutical Group Cash And Cash Equivalents Historical Data

The historical data trend for Grand Pharmaceutical Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Cash And Cash Equivalents Chart

Grand Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,059.27 1,836.70 1,752.86 1,444.01 1,339.71

Grand Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,752.86 1,034.89 1,444.01 693.61 1,339.71

Grand Pharmaceutical Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Grand Pharmaceutical Group  (HKSE:00512) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Grand Pharmaceutical Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group (HKSE:00512) Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.
Executives
Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Hu Kaijun 2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited 2101 Beneficial owner
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd. 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Citic Group Corporation 2201 Interest of corporation controlled by you
Citic Limited 2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited 2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited 2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines